Etavopivat Reduces Incidence of Vaso-occlusive Crises in Patients With Sickle Cell Disease: Hibiscus Trial Phase 2 Results through 52 Weeks

Wufsus, A., Delicou, S., El Rassi, F., Andemariam, B., Abboud, M. R., Kanter, J., Telen, M. J., Githanga, J., Inati, A., Idris, I. M., Navani, S., Wu, E., & Eisenberger, A. (2025). Etavopivat Reduces Incidence of Vaso-occlusive Crises in Patients With Sickle Cell Disease: Hibiscus Trial Phase 2 Results through 52 Weeks. Journal of Sickle Cell Disease, 2(Supplement_1). https://doi.org/10.1093/jscdis/yoaf013.002

Authors:

Adam R. Wufsus

Sophia Delicou

Fuad El Rassi

Biree Andemariam

Miguel R. Abboud

Julie Kanter

Marilyn J. Telen

Jessie Githanga

Adlette Inati

Ibrahim M. Idris

Sunil Navani